HK1198358A1 - Sustained release composition of prostacyclin - Google Patents
Sustained release composition of prostacyclinInfo
- Publication number
- HK1198358A1 HK1198358A1 HK14111869A HK14111869A HK1198358A1 HK 1198358 A1 HK1198358 A1 HK 1198358A1 HK 14111869 A HK14111869 A HK 14111869A HK 14111869 A HK14111869 A HK 14111869A HK 1198358 A1 HK1198358 A1 HK 1198358A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prostacyclin
- sustained release
- release composition
- composition
- sustained
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177411 | 2011-08-12 | ||
| EP11178075 | 2011-08-19 | ||
| EP12165512 | 2012-04-25 | ||
| PCT/EP2012/065742 WO2013024051A1 (en) | 2011-08-12 | 2012-08-10 | Sustained release composition of prostacyclin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1198358A1 true HK1198358A1 (en) | 2015-04-10 |
Family
ID=46704611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14111869A HK1198358A1 (en) | 2011-08-12 | 2014-11-24 | Sustained release composition of prostacyclin |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9872864B2 (en) |
| EP (1) | EP2741738A1 (en) |
| JP (1) | JP2014522878A (en) |
| KR (1) | KR20140082649A (en) |
| CN (1) | CN103874480A (en) |
| AU (1) | AU2012296953B2 (en) |
| BR (1) | BR112014003240A2 (en) |
| CA (1) | CA2843881C (en) |
| HK (1) | HK1198358A1 (en) |
| IL (1) | IL230711A0 (en) |
| MX (1) | MX2014001496A (en) |
| WO (1) | WO2013024051A1 (en) |
| ZA (1) | ZA201400976B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3009815B1 (en) | 2003-10-27 | 2022-09-07 | The General Hospital Corporation | Method and apparatus for performing optical imaging using frequency-domain interferometry |
| US20150087688A1 (en) * | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| ES2805367T3 (en) | 2013-01-11 | 2021-02-11 | Corsair Pharma Inc | Treprostinil prodrugs |
| JP6263604B2 (en) * | 2013-03-25 | 2018-01-17 | ユナイテッド セラピューティクス コーポレイション | Method for producing PEGylated prostacyclin compound having thiol linker |
| US9758465B2 (en) | 2013-04-30 | 2017-09-12 | United Therapeutics Corporation | Controlled release pharmaceutical formulations |
| JP6491203B2 (en) | 2013-10-25 | 2019-03-27 | インスメッド インコーポレイテッド | Prostacyclin compounds, compositions and methods of use thereof |
| ES2908142T3 (en) * | 2014-06-13 | 2022-04-27 | United Therapeutics Corp | Treprostinil formulations |
| TW201618783A (en) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on BTK occupancy and BTK resynthesis rate |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| US10343979B2 (en) | 2014-11-18 | 2019-07-09 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| EP3192502A1 (en) * | 2016-01-15 | 2017-07-19 | Sandoz Ag | Pharmaceutical composition of selexipag |
| SG11201806092TA (en) | 2016-03-01 | 2018-08-30 | Ascendis Pharma Bone Diseases As | Pth prodrugs |
| AU2017261317A1 (en) | 2016-05-05 | 2018-12-13 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
| RU2757903C2 (en) | 2016-09-15 | 2021-10-22 | Камурус Аб | Prostacyclin analogue preparations |
| KR102611820B1 (en) * | 2016-09-29 | 2023-12-07 | 아센디스 파마 본 디지즈 에이/에스 | PTH compounds with low peak-to-trough ratios |
| US11590207B2 (en) * | 2016-09-29 | 2023-02-28 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release PTH compound |
| JOP20190204A1 (en) | 2017-03-08 | 2019-09-05 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising selexipag |
| JOP20190245A1 (en) | 2017-04-20 | 2019-10-15 | Novartis Ag | Sustained release delivery systems comprising traceless linkers |
| US11040008B2 (en) * | 2018-04-04 | 2021-06-22 | Slayback Pharma Llc | Pharmaceutical compositions of meloxicam |
| TW202027794A (en) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | Sustained delivery of angiopoetin-like 3 polypeptides |
| JP7455144B2 (en) | 2019-04-29 | 2024-03-25 | インスメッド インコーポレイテッド | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
| EP4048235A1 (en) | 2019-10-23 | 2022-08-31 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising selexipag |
| US20230113077A1 (en) | 2020-01-31 | 2023-04-13 | Actelion Pharmaceuticals Ltd | Controlled release selexipag composition |
| WO2023131608A1 (en) | 2022-01-04 | 2023-07-13 | Actelion Pharmaceuticals Ltd | Controlled release compositions |
| CN115448839A (en) * | 2022-10-14 | 2022-12-09 | 广州楷石医药有限公司 | Tryprostinil prodrug |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2351112A1 (en) | 1975-10-21 | 1977-12-09 | Wellcome Found | Prostaglandin derivs. |
| US3984400A (en) | 1975-10-21 | 1976-10-05 | Pfizer Inc. | 11-Desoxy-16-aryl-ω-tetranorprostaglandins |
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| CA1241324A (en) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Interphenylene carbacyclin derivatives |
| KR20020012169A (en) * | 1999-03-31 | 2002-02-15 | 유나이티드 쎄러퓨틱스 코포레이션 | Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertention |
| US6242482B1 (en) | 2000-06-05 | 2001-06-05 | United Therapeutics Corporation | Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| EP1625856A1 (en) | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel polymeric conjugates of a prodrug |
| JP5528710B2 (en) * | 2006-02-28 | 2014-06-25 | オリガシス コーポレイション | Polymer conjugate containing acryloyloxyethyl phosphorylcholine and process for producing the same |
| JP2010518122A (en) * | 2007-02-09 | 2010-05-27 | ユナイテッド セラピューティクス コーポレーション | Treprostinil treatment for interstitial lung disease and asthma |
| ES2875426T3 (en) | 2008-04-29 | 2021-11-10 | Ascendis Pharma Endocrinology Div A/S | Pegylated Recombinant Human Growth Hormone Compounds |
| KR101671537B1 (en) | 2008-08-11 | 2016-11-01 | 넥타르 테라퓨틱스 | Multi-arm polymeric alkanoate Conjugates |
| WO2011012721A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Carrier linked pramipexole prodrugs |
| LT2459220T (en) * | 2009-07-31 | 2020-12-28 | Ascendis Pharma A/S | Biodegradable polyethylene glycol based water-insoluble hydrogels |
| WO2011042450A1 (en) * | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Carrier linked paliperidone prodrugs |
-
2012
- 2012-08-10 MX MX2014001496A patent/MX2014001496A/en unknown
- 2012-08-10 CA CA2843881A patent/CA2843881C/en not_active Expired - Fee Related
- 2012-08-10 JP JP2014524412A patent/JP2014522878A/en active Pending
- 2012-08-10 EP EP12748423.6A patent/EP2741738A1/en not_active Withdrawn
- 2012-08-10 BR BR112014003240A patent/BR112014003240A2/en not_active Application Discontinuation
- 2012-08-10 US US14/238,147 patent/US9872864B2/en not_active Expired - Fee Related
- 2012-08-10 WO PCT/EP2012/065742 patent/WO2013024051A1/en active Application Filing
- 2012-08-10 CN CN201280050069.4A patent/CN103874480A/en active Pending
- 2012-08-10 KR KR1020147006346A patent/KR20140082649A/en not_active Application Discontinuation
- 2012-08-10 AU AU2012296953A patent/AU2012296953B2/en not_active Ceased
-
2014
- 2014-01-29 IL IL230711A patent/IL230711A0/en unknown
- 2014-02-10 ZA ZA2014/00976A patent/ZA201400976B/en unknown
- 2014-11-24 HK HK14111869A patent/HK1198358A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2843881C (en) | 2020-05-26 |
| AU2012296953A1 (en) | 2014-02-20 |
| JP2014522878A (en) | 2014-09-08 |
| CA2843881A1 (en) | 2013-02-21 |
| US9872864B2 (en) | 2018-01-23 |
| BR112014003240A2 (en) | 2017-03-01 |
| IL230711A0 (en) | 2014-03-31 |
| KR20140082649A (en) | 2014-07-02 |
| MX2014001496A (en) | 2014-04-30 |
| US20140303245A1 (en) | 2014-10-09 |
| WO2013024051A1 (en) | 2013-02-21 |
| ZA201400976B (en) | 2015-08-26 |
| EP2741738A1 (en) | 2014-06-18 |
| AU2012296953B2 (en) | 2016-10-20 |
| CN103874480A (en) | 2014-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1198358A1 (en) | Sustained release composition of prostacyclin | |
| IL229830B (en) | Novel compinds as modulatord of gpr-119 | |
| EP2637696A4 (en) | Sustained release compositions | |
| IL228609A0 (en) | Sustaned slver release composition for waeter purification | |
| EP2785333A4 (en) | Amphipathic lipid-based sustained release compositions | |
| EP2742051A4 (en) | Amorphous form of dolutegravir | |
| ZA201202474B (en) | Controlled release compositions | |
| ZA201400330B (en) | Novel composition | |
| EP2730619A4 (en) | Composition | |
| PT2739276T (en) | Antiseptic composition | |
| HK1203355A1 (en) | Uses of 4-desferrithiocin analogs 4- | |
| EP2692796A4 (en) | Composition | |
| GB201107181D0 (en) | Deodorising composition | |
| EP2707338A4 (en) | Slow release phosphocement | |
| EP2768481A4 (en) | Compositions for reduction of side effects | |
| EP2684869A4 (en) | Preparation of 3-mercaptopropionates | |
| EP2680843A4 (en) | Derivatives of pyrazole-substituted amino-heteroaryl compounds | |
| GB201108912D0 (en) | Composition | |
| GB201103964D0 (en) | Composition | |
| IL230977A (en) | Crystalline form of rilapladib | |
| GB201113815D0 (en) | Multi-photon isomerisation of transcombretastatins | |
| GB201115211D0 (en) | Composition | |
| EP2785723A4 (en) | Difluoromethylation of unsaturated compounds | |
| EP2702991A4 (en) | A composition of entacopone | |
| EP2711011A4 (en) | Panaxadiol-containing composition |